Versatile and on-demand biologics co-production in yeast.

Nat Commun
Authors
Keywords
Abstract

Current limitations to on-demand drug manufacturing can be addressed by technologies that streamline manufacturing processes. Combining the production of two or more drugs into a single batch could not only be useful for research, clinical studies, and urgent therapies but also effective when combination therapies are needed or where resources are scarce. Here we propose strategies to concurrently produce multiple biologics from yeast in single batches by multiplexing strain development, cell culture, separation, and purification. We demonstrate proof-of-concept for three biologics co-production strategies: (i) inducible expression of multiple biologics and control over the ratio between biologic drugs produced together; (ii) consolidated bioprocessing; and (iii) co-expression and co-purification of a mixture of two monoclonal antibodies. We then use these basic strategies to produce drug mixtures as well as to separate drugs. These strategies offer a diverse array of options for on-demand, flexible, low-cost, and decentralized biomanufacturing applications without the need for specialized equipment.

Year of Publication
2018
Journal
Nat Commun
Volume
9
Issue
1
Pages
77
Date Published
2018 01 08
ISSN
2041-1723
DOI
10.1038/s41467-017-02587-w
PubMed ID
29311542
PubMed Central ID
PMC5758815
Links